- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03118492
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis
A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To evaluate the safety and tolerability of reduced-intensity (fludarabine/melphalan) haploidentical hematopoietic cell transplantation (Haplo-HCT) followed by post-transplant cyclophosphamide (PTCy) in patients with advanced myelofibrosis (MF), as assessed by the evaluation of toxicities, including type, frequency, severity, attribution, time course and duration.
SECONDARY OBJECTIVES:
I. To summarize and evaluate hematologic (neutrophil and platelet) recovery. II. To evaluate and describe cytokine release syndrome (CRS) post haploidentical HCT in the setting of advanced myelofibrosis, as assessed by grade, frequency, severity, duration and reversibility (outcome).
III. To estimate graft failure-free survival (GFS) at 100-days post-transplant. IV. To estimate overall survival (OS), progression-free survival (PFS) and cumulative incidence (CI) of relapse/progression, and non-relapse mortality (NRM) at 100-days, 1-year, and 2-year post transplant.
V. To estimate the cumulative incidence of acute graft-versus-host disease (GvHD), grade II-IV, at 100-days post-transplant (per Keystone Consensus modification of the Glucksberg criteria).
VI. To estimate the cumulative incidence of chronic GvHD at 1-year and 2-year post transplant (per National Institutes of Health [NIH] Consensus Criteria).
VII. To characterize the severity and extent of acute and chronic GvHD.
EXPLORATORY OBJECTIVE:
I. To conduct correlative studies and describe inflammatory cytokine levels and GVHD biomarker levels in plasma and T cell differentiation/functions in patients enrolled onto the trial.
OUTLINE:
Patients receive melphalan intravenously (IV) over 30 minutes on day -5, fludarabine IV over 30-60 minutes on days -5 to -2. Patients undergo total body irradiation (TBI) on day -1 and hematopoietic cell transplantation (HCT) on day 0. Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Starting on day 5, patients receive tacrolimus IV then orally (PO) for 6 months followed by a taper, mycophenolate mofetil PO thrice daily (TID) until day 35, and glycosylated recombinant human G-CSF AVI-014 (G-CSF) IV daily until absolute neutrophil count > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
After completion of study treatment, patients are followed for up to 2 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope Comprehensive Cancer Center
-
Contact:
- Monzr M. Al Malki
- Phone Number: 62405 626-256-4673
- Email: malmalki@coh.org
-
Principal Investigator:
- Monzr M. Al Malki
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of primary of secondary myelofibrosis with transplant indication by Dynamic International Prognostic Scoring System (DIPSS)-plus (> intermediate-1)
- Patients >= age 50 must have a comorbidity score (hematopoietic cell transplant-comorbidity index [HCT-CI]) < 4 (Sorror)
- Patients can be in chronic phase (CP) with bone marrow (BM) blast count =< 15% as long as no evidence of disease acceleration per principal investigator (PI) and treating physician's opinion or after progression to acute myeloid leukemia (AML) and achieved =< 5% BM blasts (morphologic complete remission [CR] prior to transplant)
- Lack of an human leukocyte antigen (HLA) matched donor or need to proceed fast to transplantation when a patient does not have an immediately available matched unrelated donor (typed by high-resolution in the registry)
- Performance status >= 70% (Karnofsky); patients > 50 years should have adequate cognitive function; any concerns regarding cognitive function should be addressed by a geriatrician/neurologist
- Alanine aminotransferase (ALT)/aspartate aminotransferase (AST)/bilirubin =< 5 X upper limit of normal (ULN)
- Measured creatinine clearance > 60 mls/min
- Left ventricular ejection fraction (LVEF) >= 50%
- Corrected carbon monoxide diffusing capability (DLCOc) >= 50%
- No active infections
- Prior treatment with JAK2 inhibitor therapy is not excluded; a JAK2 inhibitor will need to be stopped 1-2 days prior to starting conditioning regimen
- DONOR: Documented informed consent per local, state and federal guidelines
DONOR: Genotypically haploidentical as determined by HLA typing
- Preferably a non-maternal HLA haploidentical relative due to data of high incidence of graft failure with use of maternal HLA haploidentical cells
- Eligible donors include biological parents, siblings or half-siblings, children, or cousins in rare instances
- DONOR: Absence of pre-existing donor-specific anti-HLA antibodies (DSA) in the recipient; Patients with pre-existing DSA could undergo desensitization per City of Hope (COH) standard operating procedures [SOP] and should have DSA < MFI of 2000 prior to conditioning at discretion of PI
DONOR: Infectious disease screening performed within 30 days prior to stem cell mobilization per federal guidelines and is:
- Seronegative for HIV 1+2 antibody (Ab) and/or HIV polymerase chain reaction (PCR), human T-cell leukemia virus (HTLV) I/II Ab, hepatitis B virus surface antigen (HBsAg), hepatitis B virus surface antibody (HBcAb), hepatitis C virus (HCV) Ab
- Negative rapid plasma reagin (RPR) for syphilis
- DONOR: Women of childbearing potential (WOCBP): Urine pregnancy testing performed within 7 days prior to stem cell mobilization
- DONOR: Is approved and completed evaluation prior to recipient initiation of the preparative regimen per institutional guidelines
Exclusion Criteria:
- Evidence of severe portal hypertension with evidence of decompensation either with bleeding varices, large volume ascites, or hepatic encephalopathy
In a bone marrow biopsy 4 weeks prior to start of conditioning on study:
- > 15% bone marrow blasts at transplant if no history of AML and per PI and treating physician's opinion of disease acceleration
- > 5% if had previous progression to AML
- Human immunodeficiency virus (HIV) positive; active hepatitis B or C
- Patients with active infections; the PI is the final arbiter of the eligibility
- Patients with evidence of severe pulmonary hypertension by echocardiogram and confirmed by a subsequent right side cardiac catheterization pre-enrollment
- Liver cirrhosis
- Prior central nervous system (CNS) involvement by tumor cells
- History of another primary malignancy that has not been in remission for at least 3 years (the following are exempt from the 3-year limit: non-melanoma skin cancer, fully excised melanoma in situ [stage 0], curatively treated localized prostate cancer, and cervical or breast carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou [PAP] smear)
- Positive beta human chorionic gonadotropin (HCG) test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization
- Noncompliance - inability or unwillingness to comply with medical recommendations regarding therapy or follow-up, including smoking tobacco
- DONOR: Has undergone solid organ, stem cell, bone marrow or blood transplantation
- DONOR: Receiving any investigational agents, or concurrent biological, chemotherapy, immunosuppression or radiation therapy
- DONOR: Active infection
- DONOR: Thrombocytopenia < 150,000 cells /mm^3 at baseline evaluation
- DONOR: Sero-positive for HIV-1 & 2 antibody, HTLV-I & II antibody, hepatitis B virus (HBV) and HCV
- DONOR: Medical or physical reason which makes the donor unlikely to tolerate or cooperate with growth factor therapy and leukapheresis
- DONOR: Factors which place the donor at increased risk for complications from leukapheresis or G-CSF therapy
- DONOR: WOCBP: Pregnant or =< 6 months breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (combination chemotherapy, TBI, HCT)
Patients receive melphalan IV over 30 minutes on day -5, fludarabine IV over 30-60 minutes on days -5 to -2.
Patients undergo TBI on day -1 and HCT on day 0. Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Starting on day 5, patients receive tacrolimus IV then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 35, and G-CSF IV daily until absolute neutrophil count > 1,500/mm^3 for 3 consecutive days.
Treatment continues in the absence of disease progression or unexpected toxicity.
|
Correlative studies
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given PO
Other Names:
Undergo TBI
Other Names:
Given IV or PO
Other Names:
Undergo HCT
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 100 days post-hematopoietic cell transplantation (HCT)
|
Assessed by Bearman Toxicity Scale and National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version (CTCAE) 4.03.
Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study regimen and reversibility or outcome.
|
Up to 100 days post-hematopoietic cell transplantation (HCT)
|
Incidence of unacceptable toxicity
Time Frame: Up to 2 years
|
Assessed by Bearman Toxicity Scale and NCI CTCAE version 4.03.
Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study regimen and reversibility or outcome.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neutrophil recovery
Time Frame: Up to 2 years
|
Defined as the first of 3 measurements on different days when the patient has an absolute neutrophil count of >= 500/uL after conditioning.
|
Up to 2 years
|
Platelet recovery
Time Frame: Up to 2 years
|
Defined as the first day of a minimum of 3 measurements on different days that the patient has achieved a platelet count >= 20,000/uL and did not receive a platelet transfusion in the previous 7 days.
|
Up to 2 years
|
Incidence of cytokine release syndrome (CRS)
Time Frame: After haploidentical HCT, assessed up to 2 years
|
Defined and graded per American Society for Transplantation and Cellular Therapy (ASTCT) criteria.
|
After haploidentical HCT, assessed up to 2 years
|
Graft failure-free survival
Time Frame: Time from start of protocol treatment/infusion of stem cell product to graft-failure, death (from any cause), or last contact, whichever occurs first, assessed up to 2 years
|
Will be calculated using Kaplan-Meier product-limit method, 95% confidence intervals will be calculated.
|
Time from start of protocol treatment/infusion of stem cell product to graft-failure, death (from any cause), or last contact, whichever occurs first, assessed up to 2 years
|
Overall survival
Time Frame: Time from start of protocol treatment/infusion of stem cell product to death (from any cause), or last contact, whichever occurs first, assessed up to 36 months
|
Will be calculated using Kaplan-Meier product-limit method, 95% confidence intervals will be calculated.
|
Time from start of protocol treatment/infusion of stem cell product to death (from any cause), or last contact, whichever occurs first, assessed up to 36 months
|
Progression-free survival
Time Frame: Time from start of protocol treatment/infusion of stem cell product to, relapse, progression, death (from any cause), or last contact, whichever occurs first, assessed up to 2 years
|
Will be calculated using Kaplan-Meier product-limit method, 95% confidence intervals will be calculated.
|
Time from start of protocol treatment/infusion of stem cell product to, relapse, progression, death (from any cause), or last contact, whichever occurs first, assessed up to 2 years
|
Cumulative incidence of relapse/progression
Time Frame: Up to 2 years
|
The cumulative incidence of relapse/progression will be estimated using the method described by Gooley et al. (1999).
|
Up to 2 years
|
Non-relapse mortality (NRM)
Time Frame: Up to 2 years
|
The cumulative incidence of NRM will be estimated using the method described by Gooley et al. (1999).
|
Up to 2 years
|
Cumulative incidence of acute graft versus host disease (GvHD)
Time Frame: Up to day 100 post-HCT
|
Assessed by Keystone Consensus criteria.
Time to the first day of acute GvHD onset (of any grade) will be used to estimate the cumulative incidence.
|
Up to day 100 post-HCT
|
Cumulative incidence of chronic graft versus host disease GvHD
Time Frame: Up to 2 years post-HCT
|
Assessed by National Institutes of Health Consensus Criteria.
Time to the first day of chronic GvHD onset (of any grade) will be used to estimate the cumulative incidence.
|
Up to 2 years post-HCT
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Monzr M Al Malki, City of Hope Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Neoplastic Processes
- Primary Myelofibrosis
- Neoplasm Metastasis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antitubercular Agents
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Cyclophosphamide
- Melphalan
- Fludarabine
- Tacrolimus
- Mycophenolic Acid
- Mechlorethamine
- Nitrogen Mustard Compounds
Other Study ID Numbers
- 16420 (Other Identifier: City of Hope Medical Center)
- P30CA033572 (U.S. NIH Grant/Contract)
- NCI-2017-00613 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Secondary Myelofibrosis
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Incyte CorporationActive, not recruitingPrimary Myelofibrosis | Secondary MyelofibrosisUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedPrimary Myelofibrosis | Secondary MyelofibrosisUnited States
-
Fred Hutchinson Cancer CenterRecruitingPrimary Myelofibrosis | Secondary MyelofibrosisUnited States
-
Fred Hutchinson Cancer CenterRecruitingPrimary Myelofibrosis | Secondary MyelofibrosisUnited States
-
Geron CorporationCompletedPrimary Myelofibrosis | Secondary Myelofibrosis | Myeloid MalignanciesUnited States
-
Institut für Klinische Krebsforschung IKF GmbH...Celgene International II S.á.r.l.; Prof. F. Heidel, MH HannoverRecruiting
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedPrimary Myelofibrosis | Secondary MyelofibrosisUnited States
-
National Cancer Institute (NCI)Active, not recruitingPrimary Myelofibrosis | Secondary MyelofibrosisUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingPrimary Myelofibrosis | Secondary MyelofibrosisUnited States
-
University of UlmActive, not recruitingPrimary Myelofibrosis | Secondary Myelofibrosis | Post-PV MF | PMF | SMF | Post-ET MFGermany
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States